About
Epilepsy Therapy
Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by regulating the neuronal activity set point by reducing the neuronal mean firing rate. Selene aims to develop small molecules for inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme located on the inner mitochondrial membrane that participates in several key cellular homeostatic processes. The company is part of the FuturX biotech incubator in Ness Ziona.
Identity
| Name | Selene Therapeutics |
|---|---|
| Slug | selene-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LPGuIwJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon St 2, Ness Ziyyona, Israel |
Web & social
| Website | https://www.futurx.co.il/cgi-sys/suspendedpage.cgi |
|---|---|
| https://www.linkedin.com/company/75889240 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
epilepsydrug-developmenttreatmentspharmaceuticalsneurology
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}